These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

91 related articles for article (PubMed ID: 1452223)

  • 21. Resistance to viral infection by intraepithelial lymphocytes in HIV-1 P18-I10-specific T-cell receptor transgenic mice.
    Kuribayashi H; Wakabayashi A; Shimizu M; Kaneko H; Norose Y; Nakagawa Y; Wang J; Kumagai Y; Margulies DH; Takahashi H
    Biochem Biophys Res Commun; 2004 Apr; 316(2):356-63. PubMed ID: 15020225
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Neutralization of primary and T-cell line adapted isolates of human immunodeficiency virus type 1: role of V3-specific antibodies.
    Beddows S; Louisirirotchanakul S; Cheingsong-Popov R; Easterbrook PJ; Simmonds P; Weber J
    J Gen Virol; 1998 Jan; 79 ( Pt 1)():77-82. PubMed ID: 9460926
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The immune response to HIV: implications for vaccine development.
    Bolognesi DP
    Semin Immunol; 1993 Jun; 5(3):203-14. PubMed ID: 8347841
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Biological consequences of human immunodeficiency virus type 1 envelope polymorphism: does variation matter? 1995 Fleming Lecture.
    McKeating JA
    J Gen Virol; 1996 Dec; 77 ( Pt 12)():2905-19. PubMed ID: 9000081
    [No Abstract]   [Full Text] [Related]  

  • 25. A Chimeric HIV-1 gp120 Fused with Vaccinia Virus 14K (A27) Protein as an HIV Immunogen.
    Vijayan A; García-Arriaza J; Raman SC; Conesa JJ; Chichón FJ; Santiago C; Sorzano CÓ; Carrascosa JL; Esteban M
    PLoS One; 2015; 10(7):e0133595. PubMed ID: 26208356
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Vaccine-elicited V3 loop-specific antibodies in rhesus monkeys and control of a simian-human immunodeficiency virus expressing a primary patient human immunodeficiency virus type 1 isolate envelope.
    Letvin NL; Robinson S; Rohne D; Axthelm MK; Fanton JW; Bilska M; Palker TJ; Liao HX; Haynes BF; Montefiori DC
    J Virol; 2001 May; 75(9):4165-75. PubMed ID: 11287566
    [TBL] [Abstract][Full Text] [Related]  

  • 27. B cell epitope mapping of human immunodeficiency virus envelope glycoproteins with long (19- to 36-residue) synthetic peptides.
    Neurath AR; Strick N; Lee ES
    J Gen Virol; 1990 Jan; 71 ( Pt 1)():85-95. PubMed ID: 1689372
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Recognition of two overlapping CTL epitopes in HIV-1 p17 by CTL from a long-term nonprogressing HIV-1-infected individual.
    Harrer T; Harrer E; Barbosa P; Kaufmann F; Wagner R; Brüggemann S; Kalden JR; Feinberg M; Johnson RP; Buchbinder S; Walker BD
    J Immunol; 1998 Nov; 161(9):4875-81. PubMed ID: 9794421
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Design of immunogens that present the crown of the HIV-1 V3 loop in a conformation competent to generate 447-52D-like antibodies.
    Chakraborty K; Durani V; Miranda ER; Citron M; Liang X; Schleif W; Joyce JG; Varadarajan R
    Biochem J; 2006 Nov; 399(3):483-91. PubMed ID: 16827663
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Expression and functional activity of isotype and subclass switched human monoclonal antibody reactive with the base of the V3 loop of HIV-1 gp120.
    Liu F; Bergami PL; Duval M; Kuhrt D; Posner M; Cavacini L
    AIDS Res Hum Retroviruses; 2003 Jul; 19(7):597-607. PubMed ID: 12908937
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Generation and characterization of a bivalent protein boost for future clinical trials: HIV-1 subtypes CR01_AE and B gp120 antigens with a potent adjuvant.
    Wen Y; Trinh HV; Linton CE; Tani C; Norais N; Martinez-Guzman D; Ramesh P; Sun Y; Situ F; Karaca-Griffin S; Hamlin C; Onkar S; Tian S; Hilt S; Malyala P; Lodaya R; Li N; Otten G; Palladino G; Friedrich K; Aggarwal Y; LaBranche C; Duffy R; Shen X; Tomaras GD; Montefiori DC; Fulp W; Gottardo R; Burke B; Ulmer JB; Zolla-Pazner S; Liao HX; Haynes BF; Michael NL; Kim JH; Rao M; O'Connell RJ; Carfi A; Barnett SW
    PLoS One; 2018; 13(4):e0194266. PubMed ID: 29698406
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Detection of primary cytotoxic T lymphocytes specific for the envelope glycoprotein of HIV-1 by deletion of the env amino-terminal signal sequence.
    McChesney M; Tanneau F; Regnault A; Sansonetti P; Montagnier L; Kieny MP; Rivière Y
    Eur J Immunol; 1990 Jan; 20(1):215-20. PubMed ID: 2106442
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Use of retroviral vectors for the analysis of SIV/HIV-specific CD8 T cell responses.
    Negri DR; Buffa V; Leone P; Bona R; Borghi M; Carlini F; De Angelis F; Indraccolo S; Ensoli B; Cara A
    J Immunol Methods; 2004 Aug; 291(1-2):153-63. PubMed ID: 15345313
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Patterns of nucleotide substitutions and implications for the immunological diversity of human immunodeficiency virus.
    Shimizu N; Okamoto T; Moriyama EN; Takeuchi Y; Gojobori T; Hoshino H
    FEBS Lett; 1989 Jul; 250(2):591-5. PubMed ID: 2753154
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Inhibitory mechanism of anti-P30-52 monoclonal antibody against human immunodeficiency virus type 1 (HIV-1) multiplication in infected MT-4 cells.
    Ota A; Ueda S
    Hybridoma; 1999 Jun; 18(3):235-41. PubMed ID: 10475237
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Induction of rapid apoptosis for class I MHC molecule-restricted CD8(+) HIV-1 gp160-specific murine activated CTLs by free antigenic peptide in vivo.
    Nakagawa Y; Shimizu M; Norose Y; Takahashi M; Takahashi H
    Int Immunol; 2013 Jan; 25(1):11-24. PubMed ID: 22945875
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Assessment of HIV-1 antigenic diversification using serum as sample source.
    Goudsmit J; Zwart G; Wolfs T
    AIDS Res Hum Retroviruses; 1992 Aug; 8(8):1473. PubMed ID: 1466985
    [No Abstract]   [Full Text] [Related]  

  • 38. HIV/AIDS Vaccine Candidates Based on Replication-Competent Recombinant Poxvirus NYVAC-C-KC Expressing Trimeric gp140 and Gag-Derived Virus-Like Particles or Lacking the Viral Molecule B19 That Inhibits Type I Interferon Activate Relevant HIV-1-Specific B and T Cell Immune Functions in Nonhuman Primates.
    García-Arriaza J; Perdiguero B; Heeney JL; Seaman MS; Montefiori DC; Yates NL; Tomaras GD; Ferrari G; Foulds KE; Roederer M; Self SG; Borate B; Gottardo R; Phogat S; Tartaglia J; Barnett SW; Burke B; Cristillo AD; Weiss DE; Lee C; Kibler KV; Jacobs BL; Wagner R; Ding S; Pantaleo G; Esteban M
    J Virol; 2017 May; 91(9):. PubMed ID: 28179536
    [TBL] [Abstract][Full Text] [Related]  

  • 39. HIV-1 evolution and disease progression.
    Nowak MA; Anderson RM; Boerlijst MC; Bonhoeffer S; May RM; McMichael AJ
    Science; 1996 Nov; 274(5289):1008-11. PubMed ID: 8966557
    [No Abstract]   [Full Text] [Related]  

  • 40. [Molecular analysis of the principal neutralization epitope (V3 loop) of human immunodeficiency virus type 1 in Argentina].
    Gómez Carrillo M; Piccardo C; Libonatti O
    Rev Argent Microbiol; 1992; 24(2):91-101. PubMed ID: 1298019
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.